Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
Year: 2022
Type: article
Study design: Observational Study
Abstract: Omicron, a novel SARS-CoV-2 variant has emerged and is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing activity in serum of convalescent or vaccinated individuals to understand potential loss of protection from infection or re-infection. Two doses of BNT162b2 or CoronaVac vaccines provided little 50% plaque reduction neutralization test (PRNT50) antibody immunity against the Omicron variant, even at one-month post vaccination. Booster doses with BNT162b2 in those with two doses of either BNT162b2 or CoronaVac provided acceptable neutralizing immunity against Omicron variant at 1-month post-booster dose. However, three doses of BNT162b2 elicited higher levels of PRNT50 antibody to Omicron variant suggesting longer duration of protection. Convalescent from SARS-CoV-2 infection did not have protective PRNT50 antibody levels to Omicron, but a single dose of BNT162b2 vaccine provided protective immunity. Field vaccine-efficacy studies against Omicron variant against different vaccines are urgently needed.
Source: Nature Medicine
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: National Research Foundation, National Natural Science Foundation of China, Research Grants Council, University Grants Committee, Innovation and Technology Commission, National Research Foundation of Korea, Food and Health Bureau, National Institutes of Health, Health and Medical Research Fund, National Institute of Allergy and Infectious Diseases
Awards: G1396843103, G1600422354, Emerging infections: surveillance, epidemiology and pathogenesis, G2503753333, G2954676493, Community based sero-epidemiological study of COVID19 to provide data in real time on agestratified infection attack rates, disease severity and population-immunity, for guiding intervention policy., G4365416464, G5514976981, G6256444366, G6401049725, Long-term longitudinal comparisons of health status and immune responses in convalescent COVID-19 and vaccinated cohorts in Hong Kong, G7070478564, G7843736458, G8321338699, G8416600932
OpenAlex ID: W4205240144